Duligotuzumab: Human anti-EGFR/anti-HER3 MAb colorectal cancer therapy head and neck cancer therapy

Drugs of the Future

Volumn 40, Issue 3, 2015, Pages 167-172

  Cole, P ^a  

^a THOMSON REUTERS   (United Kingdom)

Author keywords

Anti EGFR; Anti HER3 ErbB3; Colorectal cancer; Duligotuzumab; Head and neck cancer; MEHD 7945A

Indexed keywords

CETUXIMAB; DULIGOTUZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RECURRENCE; COLORECTAL CANCER; DRUG EFFICACY; DRUG SAFETY; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; METASTASIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); SIGNAL TRANSDUCTION; SOLID TUMOR; UNSPECIFIED SIDE EFFECT;

EID: 84930536940     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2015.040.03.2312450     Document Type: Article

References (18)

1. Eigenbrot, C., Fuh, G. Two-in-One antibodies with dual action Fabs. Curr Opin Chem Biol 2013, 17(3): 400-5.
2. Bostrom, J., Yu, S.F., Kan, D. et al. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 2009, 323(5921): 1610-4.
3. Schaefer, G., Haber, L., Crocker, L.M. et al. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 2011, 20(4): 472-86.
4. Zhang, H., Berezov, A., Wang, Q., Zhang, G., Drebin, J., Murali, R., Greene, M.I. ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest 2007, 117(8): 2051-8.
5. Schaefer, G.M. Targeting EGFR and HER3 with a "two-in-one antibody". 101st Annu Meet Proc Am Assoc Cancer Res (AACR) (April 17-21, Washington, D.C.) 2010, Abst DD01-2.
6. Huang, S., Li, C., Sliwkowski, M.X., Harari, P.M. MEHD7945A, an EGFR/ErbB3 dual specific antibody, overcomes acquired resistance to EGFR inhibitors in head and neck and lung tumors. 102nd Annu Meet Am Assoc Cancer Res (AACR) (April 2-6, Orlando) 2011, Abst 637.
7. Huang, S., Li, C., Armstrong, E.A. et al. Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation. Cancer Res 2013, 73(2): 824-33.
8. Tao, J., Ip, P., Auricchio, N., et al. Combined blockade of PI3K/AKT and EGFR/HER3 enhances anti-tumor activity in triple negative breast cancer. 35th Annu San Antonio Breast Cancer Symp (December 4-8, San Antonio) 2012, Abst S5-7.
9. Crocker, L.M., Fields, C., Shao, L., Sliwkowski, M.X., Phillips, G.D.L., Schaefer, G. The dual action antibody MEHD7945A targeting EGFR and HER3 enhances chemotherapy induced cytotoxicity in vitro and in vivo. 103rd Annu Meet Am Assoc Cancer Res (AACR) (March 31-April 4, Chicago) 2012, Abst 1212.
10. Li, C., Huang, S., Armstrong, E.A., Sliwkowski, M.X., Amler, L.C., Harari, P.M. MEHD7945A, dual specific antibody against EGFR and HER3, augments radiation response in head and neck squamous cell carcinoma. 103rd Annu Meet Am Assoc Cancer Res (AACR) (March 31-April 4, Chicago) 2012, Abst 2721.
11. Penuel, E.M., Burton, L., Stern, H., Mark, L., Pirzkall, A., Amler, L., Schaefer, G. Assessing signal modulation in preclinical models and tumor tissue from patients enrolled in a phase 1 study of the HER3/EGFR dual action antibody, MEHD7945A (MEHD), as an exploratory pharmacodynamic (PD) analysis. 104th Annu Meet Am Assoc Cancer Res (AACR) (April 6-10, Washington, D.C.) 2013, Abst 3527.
12. Kamath, A.V., Lu, D., Gupta, P. et al. Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose. Cancer Chemother Pharmacol 2012, 69(4): 1063-9.
13. Juric, D., Dienstmann, R., Cervantes, A., et al. Pharmacodynamic (PD) assessment of drug activity in tumor tissue from patients (pts) enrolled in a Phase I study of MEHD7945A (MEHD), a first-in-class HER3/EGFR dual action antibody, in pts with locally advanced or metastatic epithelial tumors. 104th Annu Meet Am Assoc Cancer Res (AACR) (April 6-10, Washington, D.C.) 2013, Abst 3363.
14. Hidalgo, M., Calles, A., Juric, D., et al. Human pharmacokinetic (PK) characterization of the novel dual-action anti-HER3/EGFR antibody MEHD7945A (MEHD) in patients with refractory/recurrent epithelial tumors. 48th Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2012, Abst 2567.
15. Clement, P., Machiels, J., Wirth, L., et al. Phase 1b study of MEHD7945A (MEHD) plus cisplatin/fluorouracil (cis/5FU) or carboplatin/paclitaxel (carbo/pac) for 1st-line treatment of recurrent/metastatic squamous cell carcinoma of head and neck (RMSCCHN). 39th Eur Soc Med Oncol (ESMO) Congr (September 26-30, Madrid) 2014, Abst 989PD.
16. Prell, R., Danilenko, D., Wang, C. et al. Nonclinical characterization of a HER3 and EGFR dual-action antibody in cynomolgus monkeys. 51st Annu Meet Soc Toxicol (March 11-15, San Francisco) 2012, Abst 1748.
17. Juric, D., Dienstmann, R., Messersmith, W., et al. A Phase 1 study of MEHD7945A (MEHD), a first-in-class EGFR/HER3 dual action antibody, in patients (pts) with locally advanced or metastatic epithelial tumors. 103rd Annu Meet Am Assoc Cancer Res (AACR) (March 31-April 4, Chicago) 2012, Abst CT-08.
18. Fayette, J., Wirth, L., Oprean, C., et al. Randomized phase II study of MEHD7945A (MEHD) vs cetuximab (Cet) in greater than or equal to 2nd-line recurrent/metastatic squamous cell carcinoma of the head and neck (RMSCCHN) progressive on/after platinum-based chemotherapy (PtCT). 39th Eur Soc Med Oncol (ESMO) Congr (September 26-30, Madrid) 2014, Abst 9860.